Spyre Therapeutics, Inc. (SYRE)
Health Care · Pharmaceutical Preparations
Spyre Therapeutics, Inc. (SYRE) is listed on Nasdaq, where its shares have traded since April 7, 2016. SentiSense covers Spyre Therapeutics, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Cameron Turtle is its chief executive officer. The company reports 130 employees, and its corporate website is www.spyre.com.
About Spyre Therapeutics, Inc.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
Latest reported results
Spyre Therapeutics Inc. reported revenue of $0.00 for Q3 FY2026.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 258 institutions reported holding SYRE, with 95.8 million shares worth $8.5 billion in aggregate. The largest reported holders were FMR, BlackRock and Vanguard. Of the 5 largest reported holders, all 5 added shares during the quarter.
More on SYRE
- SYRE sentiment: whether news and social coverage of Spyre Therapeutics, Inc. leans bullish or bearish, and the stories driving it.
- SYRE ownership: all 258 reporting institutions, plus insider and congressional trades.
- SYRE financials: revenue, net income, operating margin and free cash flow through Q3 FY2026.
SentiSense also tracks daily options readings for Spyre Therapeutics, Inc.: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Spyre Therapeutics, Inc. do?
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases.
What sector is SYRE in?
SentiSense classifies Spyre Therapeutics, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does SYRE stock trade?
Spyre Therapeutics, Inc. (SYRE) is listed on Nasdaq, where its shares have traded since April 7, 2016.
Who is the CEO of Spyre Therapeutics, Inc.?
Cameron Turtle is the chief executive officer of Spyre Therapeutics, Inc..